Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 10, 2010, Pages 1273-1281

  Stathopoulos, Georgios T ^a,b,c   Sherrill, Taylor P ^a   Karabela, Sophia P ^b   Goleniewska, Kasia ^a   Kalomenidis, Ioannis ^b   Roussos, Charis ^b   Fingleton, Barbara ^a   Yull, Fiona E ^a   Peebles Jr , R Stokes ^a   Blackwell, Timothy S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Allergy; Eosinophils; Lung cancer; Myeloid suppressor cells; Pleural disease

Indexed keywords

INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EOSINOPHIL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALIGNANT PLEURAL EFFUSION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; PLEURA EFFUSION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-5; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PLEURAL EFFUSION, MALIGNANT;

EID: 78349288445     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201001-0001OC     Document Type: Article

References (49)

1. Light RW. Clinical practice: pleural effusion. N Engl J Med 2002;346:1971-1977.
2. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
3. Light RW, Lee YCG. Textbook of pleural diseases, 2nd ed. London: Hodder and Arnold; 2008.
4. Antunes G, Neville E, Duffy J, Ali N, on behalf of the BTS Pleural Disease Group. BTS guidelines for the management of malignant pleural effusions. Thorax 2003;58:ii29-ii38.
5. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50. (Pubitemid 27079443)
6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
7. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee. Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
8. Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003;123:221S-225S.
9. Light RW. Talc for pleurodesis? Chest 2002;122:1506-1508.
10. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004;170:377-382. (Pubitemid 39214610)
11. Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, van den Heuvel M. Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur Respir J 2008;32:1321-1327.
12. Lee YC, Wilkosz S. Malignant pleural effusions: fixing the leaky faucet. Am J Respir Crit Care Med 2008;178:3-5.
13. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, et al. Nuclear factor-κB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006;34:142-150.
14. Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, et al. Tumor necrosis factor-α promotes malignant pleural effusion. Cancer Res 2007;67:9825-9834.
15. Stathopoulos GT, Psallidas I, Moschos C, Moustaki A, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008;100:1464-1476.
16. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305.
17. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
18. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS. Epithelial nuclear factor-κB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci USA 2007;104:18514-18519.
19. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B. Host nuclear factor kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 2008;6:364-371. (Pubitemid 351416527)
20. Weissflog D, Kroegel C, Luttmann W, Grahmann PR, Hasse J. Leukocyte infiltration and secretion of cytokines in pleural drainage fluid after thoracic surgery: impaired cytokine response in malignancy and postoperative complications. Chest 1999;115:1604-1610.
21. Martínez-García MA, Cases-Viedma E, Cordero- Rodríguez PJ, Hidalgo-Ramírez M, Perpiñá-Tordera M, Sanchis-Moret F, Sanchis-Aldás JL. Diagnostic utility of eosinophils in the pleural fluid. Eur Respir J 2000;15:166-169.
22. Kalomenidis I, Light RW. Eosinophilic pleural effusions. Curr Opin Pulm Med 2003;9:254-260.
23. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000;157:1893-1903.
24. Yeh H-H, Lai W-W, Chen HHW, Liu H-S, Su W-C. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006;25:4300-4309.
25. Wardlaw AJ, Kay AB. Eosinophils and their disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams' hematology, 6th ed. New York: McGraw-Hill; 2001. p. 785.
26. Isaacson NH, Rapoport P. Eosinophilia in malignant tumors: its significance. Ann Intern Med 1946;25:893.
27. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997;12:807-812.
28. Samoszuk M, Hansen L. Detection of interleukin 5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990;75:13-16.
29. Walter R, Joller-Jemelka HI, Salomon F. Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels. Exp Hematol 2002;30:1-2.
30. Wong DT, Bowen SM, Elovic A, Gallagher GT, Weller PF. Eosinophil ablation and tumor development. Oral Oncol 1999;35:496-501.
31. Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol 2008;180:1199-1206.
32. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, Witztum JL. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004;114:427-437.
33. Schumacher JH, O'Garra A, Shrader B, van Kimmenade A, Bond MW, Mosmann TR, Coffman RL. The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 enzyme-linked immunosorbent. J Immunol 1988;141:1576-1581.
34. Porcel JM. Establishing a diagnosis of pleural effusion due to heart failure. Respirology 2009;14:471-473.
35. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Köhler G, Young IG, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996;4:15-24.
36. Schwarze J, Cieslewicz G, Hamelmann E, Joetham A, Shultz LD, Lamers MC, Gelfand EW. IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection. J Immunol 1999;162:2997-3004. (Pubitemid 29309329)
37. Garlisi CG, Kung TT, Wang P, Minnicozzi M, Umland SP, Chapman RW, Stelts D, Crawley Y, Falcone A, Myers JG, et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 1999;20:248-255.
38. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Papiris SA, Roussos C, Kalomenidis I. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008;178:50-59.
39. Eversole RR, Mackenzie CD, Beuving LJ. A photoreactive fluorescent marker for identifying eosinophils and their cytoplasmic granules in tissues. J Histochem Cytochem 2003;51:253-257.
40. Orlic D, Anderson S, Biesecker LG, Sorrentino BP, Bodine DM. Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci USA 1995;92:4601-4605.
41. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:2777-2790.
42. Stathopoulos GT, Lee YCG. Experimental models: pleural disease other than mesothelioma. In: Light RW, Lee YCG, editors. Textbook of pleural diseases, 2nd ed. London: Hodder and Arnold; 2008. p. 169-186.
43. Stathopoulos GT, Kalomenidis I. Animal models of malignant pleural effusion. Curr Opin Pulm Med 2009;15:343-352.
44. Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, Pero R, Dimina D, Ochkur SI, O'Neill K, Colbert D, et al. Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 2006;79:1131-1139.
45. McCormack MP, Gonda TJ. Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common b subunit. Oncogene 1999;18:7190-7199.
46. Huffnagle GB, Boyd MB, Street NE, Lipscomb MF. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 1998;160:2393-2400.
47. Kirman J, Zakaria Z, McCoy K, Delahunt B, Le Gros G. Role of eosinophils in the pathogenesis of Mycobacterium bovis BCG infection in gamma interferon receptor-deficient mice. Infect Immun 2000;68:2976-2978.
48. Horiuchi H, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997;17:70-77.
49. Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 2006;116:2587-2590. (Pubitemid 44511621)